One of the major trends to emerge from the biotechnology industry last year was the expiration of patents for several blockbuster drugs. As a result major biotech and pharma companies now face increasing competition from generic drugs. The key for biotech and big pharma companies will be to develop a strong pipeline of products. In addition, major biotech companies are also looking to acquire or collaborate with smaller biotech companies that are developing potential blockbuster drugs. Meanwhile, companies such as Dendreon Corp. (NASDAQ:DNDN) will look to boost sales of their recently approved drugs. Being a member of St Bulls give you the exclusivity to speak with an analyst today on DNDN. So, sign now for free at
Dendreon prostate cancer drug Provenge has already been approved by the U.S. Food and Drug Administration (FDA) in the U.S. The drug may prove to be a catalyst in the company's growth since its much awaited approvals from the European committees may happen sometime in the first quarter of this year. Also market analysts believe that sales of Provenge may actually increase as compared to last year. Provenge (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Get more insight about this momentum building event by signing up now at
Dendreon shares have risen sharply so far this year as investors expect Provenge sales to improve. Year-to-date, the stock has gained more than 27%, easily outperforming the broad market. On Monday, though, the stock saw a slight pullback. DNDN shares finished 2.75% lower at $6.72 on Monday, with volume at 7.38 million, slightly below the daily average of 7.87 million. The stock fell to an intra-day low of $6.65. Talk to our analysts and get their take on DNDN by registering now at
DNDN shares have been facing stiff resistance at around $7 in the last few weeks. If DNDN breaks through this level then there could be significant upside potential. Technical indicators for DNDN are currently giving strong bullish signals. The stock's MACD has crossed the signal line on the upside. The stock is also trading above its 50-day and 200-day moving averages. Find out why DNDN has been upgraded to a Platinum Equity by signing up to the link below
Also eagerly awaited is the Dendreon Corporations result which would be released on February 25th 2013. The earnings announcement would be done at 9 AM Eastern Time. The release would highlight the company's result for the full year and also the fourth quarter. Find out why DNDN is one of our favorite in the industry by registering at
Disclaimer: Bull Market Group LTD is not a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security. A third party, Stbulls.com has paid Bull Market Group LTD four hundred and fifty dollars for the publication of this news release. Neither Bull Market Group LTD nor the hiring party has a financial relationship with any company whose stock is mentioned in this release.
For full disclaimer visit: http://www.stbulls.com/disclaimer.html
Contact Person:
St. Bulls Inc.
Martin Peters
Marketing Consultant
info@stbulls.com
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here